Author(s) :

Vedant Shukla.

Volume/Issue :

Abstract :

Chronic myeloid leukemia (CML) was once considered a terminal diagnosis for patients. It is a rare cancer that makes up approximately 15 to 20% of all leukemia cases in the United States, with about 9,280 new cases estimated in 2024 (5,330 in men and 3,950 in women) [1]. However, in the UK, CML accounts for less than 1% of all new cancer diagnoses. The disease predominantly affects adults, with the average age of diagnosis being around 64 years, and nearly half of all cases occur in individuals aged 65 or older, the cases of CML in children being extremely rare. In 2024, the United States estimated approximately 1,280 deaths from CML [2, 3]. Before modern therapies were available, patients often endured the full progression of the disease, which typically resulted in a fatal outcome. However, the development of Gleevec (imatinib) during the early 2000s revolutionized CML treatment and marked the beginning of a new era in targeted therapy. This paper will explore Gleevec’s development, mechanism of action, and its initial application to CML as well as similarly working diseases. Moreover, Gleevec’s success has extended beyond just CML as it has proven effective in other cancers driven by similar molecular mechanisms, such as gastrointestinal stromal tumors (GIST), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This paper aims to discuss and explore Gleevec’s broader impact in treating these diseases, highlighting its role in advancing targeted cancer therapies.